The University of Alabama at Tuscaloosa has opened a search for an assistant or associate professor specializing in DMPK, PBPK, and PKPD modeling to join its faculty through the Comprehensive Cancer Center High-Throughput Screening (CCHS) initiative.
Drug metabolism and pharmacokinetics (DMPK), physiologically based pharmacokinetic (PBPK), and pharmacodynamic (PKPD) modeling represent essential quantitative disciplines in modern drug discovery. According to the University of Alabama, the new faculty position aims to bolster research capabilities in predicting how investigational therapeutics behave within biological systems, bridging the gap between early-stage high-throughput screening and preclinical development.
Faculty Role and Research Objectives
The incoming faculty member will design and execute advanced modeling studies to characterize absorption, distribution, metabolism, excretion, and toxicity profiles of novel small molecules and biologics. PBPK and PKPD models allow researchers to simulate drug concentration-time profiles in various tissues, helping teams optimize dosing regimens and select optimal clinical candidates before human trials begin.
Academic departments housing these specialized quantitative pharmacology roles typically expect faculty to secure external grant funding, publish in peer-reviewed journals, and collaborate across multidisciplinary teams spanning chemistry, oncology, and pharmacology. At Tuscaloosa, the appointment ties directly into the infrastructure of the Comprehensive Cancer Center, focusing analytical firepower on oncology drug discovery pathways.
The Growing Importance of Quantitative Pharmacology
Quantitative systems pharmacology and mechanistic modeling have transformed how pharmaceutical pipelines advance through preclinical gates. Regulatory agencies, including the U.S. Food and Drug Administration (FDA), increasingly accept PBPK modeling submissions to support first-in-human dose selection and drug-interaction risk assessments without requiring exhaustive clinical trials beforehand.
By embedding modeling experts directly into high-throughput screening environments, academic research centers can rapidly filter out compounds with unfavorable pharmacokinetic properties early in the pipeline. This integration reduces late-stage attrition rates and accelerates the translation of laboratory discoveries into viable therapeutic candidates for cancer patients.
Application and Institutional Context
Candidates holding a Ph.D., Pharm.D., or equivalent terminal degree in pharmaceutical sciences, bioengineering, pharmacokinetics, or related quantitative fields are eligible to apply through the University of Alabama’s official academic employment portal. The search committee evaluates candidates based on their publication record, potential for independent extramural funding, and demonstrated expertise in computational pharmacology software.
The recruitment effort reflects a broader nationwide trend among major research universities expanding their quantitative biology faculties to support complex translational research programs. As oncology pipelines demand increasingly sophisticated data integration, institutions are investing heavily in computational scientists capable of modeling complex biological interactions.
Related reading